ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 969

Caspase-8 Prevents Lung Fibrosis in a Murine SSc-like Disease Model By Preventing Macrophage Differentiation

Alexander Misharin1, Carla M. Cuda2, Luisa Morales-Nebreda3, Gokhan Mutlu1, GR Scott Budinger3 and Harris R. Perlman4, 1Northwestern University, Chicago, IL, 2Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, 4Northwestern University Feinberg School of Medicine, Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: fibrosis and scleroderma, Macrophage

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics I

Session Type: Abstract Submissions (ACR)

Background/Purpose Pulmonary fibrosis has emerged as the leading cause of death in patients with Systemic Sclerosis (SSc). Currently available therapies are only marginally effective in treating this devastating complication and even patients who respond to therapy are left with significant respiratory morbidity. Alternatively activated M2 macrophages have been demonstrated to be the key players in development of pulmonary fibrosis. Caspase-8 is a cysteine-aspartic acid protease was originally identified as a key initiator of the apoptotic death receptor pathway and was later found to suppress programmed necrotic cell death (necroptosis) by inhibiting the receptor-interacting serine/threonine kinase 1/3 (RIPK1/3). We have previously shown that mice deficient in caspase-8 specifically in macrophages and DCs have markedly less lung fibrosis than their littermate controls following intratracheal treatment with either bleomycin or an adenovirus encoding an active form of TGF-β. We now examined specific mechanisms, responsible for this protection.

Methods Mice lacking caspase-8 specifically in DCs or macrophages were generated (CreCD11cCasp8flox/flox and CreLysMCasp8flox/flox) and examined using the bleomycin and adenoviral TGF-β models of lung fibrosis. Flow cytometric analysis was used to characterize macrophages and DC. Luminex-based QuantiGene assay was used to determine gene expression profiles and polarization of FACS-sorted macrophages.

Results We found that in the wild type mice, monocytes, recruited into the lung from the bone marrow after instillation of bleomycin, transition through the interstitial macrophage phase into alveolar macrophages, which are virtually indistinguishable from tissue-resident alveolar macrophages. However, unlike the tissue-resident macrophages, which do not exhibit profibrotic M2 phenotype, these bone marrow-derived alveolar macrophages were M2-polarized. Mice, deficient for caspase-8 in macrophages had similar number of interstitial macrophages to WT mice, but were lacking profibrotic M2 bone marrow-derived alveolar macrophages. Moreover, expression Pparg, Tgm2, Shpk and Mertk, which are important for mature alveolar macrophage phenotype, was decreased in Caspase-8-deficient bone marrow-derived alveolar macrophages.

Conclusion Our data identified bone marrow-derived alveolar macrophages and not interstitial macrophages or tissue-resident alveolar macrophages as key players and perspective target for pulmonary fibrosis in patients with scleroderma. Moreover, these data reveals a novel role for Caspase-8 in macrophage differentiation and polarization.


Disclosure:

A. Misharin,
None;

C. M. Cuda,
None;

L. Morales-Nebreda,
None;

G. Mutlu,
None;

G. S. Budinger,
None;

H. R. Perlman,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/caspase-8-prevents-lung-fibrosis-in-a-murine-ssc-like-disease-model-by-preventing-macrophage-differentiation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology